Thursday, May 5, 2016 Last update: 1:33 AM - COMING SOON! New Features/Design as we Expand our Coverage Globally

The Best of U.S. Company Tech News - Updated Daily

Thursday, January 3, 2013

  • Posted at 6:00 AM
    MENLO PARK, CA -- (Marketwire) -- 01/03/13 -- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the European Patent Office has issued a notice of intention to grant a patent to Stanford University that will cover certain predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn's Early Embryo Viability Assessment (Eeva) Test. In addition, the U.S. Patent and Trademark Office (USPTO) has issued a ... read more
  • Posted at 6:00 AM
    LAS VEGAS, NV -- (Marketwire) -- 01/03/13 -- ZyXEL Communications, a leading provider of secure broadband networking, Internet connectivity, home entertainment and routing products, will showcase several forward-looking technologies at CES 2013, January 8-11. ZyXEL will demonstrate cloud-based entertainment and monitoring service solutions, and leading edge broadband access technology including fixed 4G / LTE. The demonstrations will be held in ZyXEL's private suite at the Renaissance Las Vegas for customers and media by appointment. ZyXEL will spotlight its LTE5121, ... read more
  • Posted at 6:00 AM
    CARLSBAD, CA -- (Marketwire) -- 01/03/13 -- International Stem Cell Corporation (OTCQB: ISCO) ( ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that Executive Vice President, Dr. Simon Craw, will present at the Biotech Showcase™ 2013 on Monday, January 7th at 9:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel. Biotech Showcase 2013 conference presentation details: Date: Monday, January 7, 2013 Time: 9:30 pm ... read more
  • Posted at 5:56 AM
    Today, Agile IT released its 2012 year-end results, showing that business is booming for this San Diego cloud computing company focused on fixed price Cloud and Office 365 Migration Solutions. "This year has been great for Agile IT," said ... read more
  • Posted at 5:54 AM announces that a new market research report is available in its catalogue: Drug Discovery Outsourcing: World Market 2013-2023 Report Details How much revenue can drug discovery outsourcing generate? Our new report shows you See what the future holds for outsourcing early-stage drug development. There is rising demand for those services. Visiongain's updated report gives you revenue predictions to 2023, showing you data, trends, opportunities and commercial prospects. Our study is your guide to the potential of those pharmaceutical services. That ... read more
  • Posted at 5:50 AM
    Science Applications International Corporation (SAIC) [NYSE: SAI] announced today it was awarded a prime contract by the U.S. Army Environmental Command (USAEC) to provide environmental remediation support services at Army installations nationwide. The multiple-award indefinite-delivery/indefinite-quantity contract has a five-year base period of performance and a total contract value of $240 million for all awardees. The USAEC leads and executes Army cleanup and environmental quality programs, providing technical expertise to enable soldier readiness and sustainable military communities. ... read more
  • Posted at 5:50 AM announces that a new market research report is available in its catalogue: Power Line Communication (PLC) Systems Market (By Technologies-Narrowband & Broadband, Products-Transmission & Distribution, Applications-Smart Grid, Home Networking, Long Haul & M2M, Voltage Network-High, Medium & Low, Verticals-Industrial, Residential & Power line communication (PLC) is a technology that enables sending communication data over electric power cables. Power line communication is used at different frequency bands depending on signal transmission characteristics of the power wiring and the application for which ... read more
  • Posted at 5:45 AM
    Based on its recent analysis of the cognitive computing processors market for pattern recognition, Frost & Sullivan recognizes CogniMem Technologies Inc. with the 2012 North American Frost & Sullivan New Product Innovation Award for its pioneering neural network system-on-chip CM1K. The most powerful computers and processors today are based on the von Neumann architecture, which often sees the processor idling while waiting for data from memory when performing real-time, high-performance computing. Apart from wasting system resources, memory bottlenecks are frequent in ... read more
  • Discovery Labs Initiates Launch of AFECTAIR® --- WARRINGTON, Pa., Jan. 3, 2013
    Posted at 5:45 AM
    Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has initiated the launch of its AFECTAIR(®) airway connector for infants receiving aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively). The AFECTAIR device simplifies the delivery of aerosolized medication to critical care patients who require ventilatory support by introducing the medication directly at the patient interface. The launch begins with ... read more
  • Posted at 5:39 AM announces that a new market research report is available in its catalogue: Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 Report Details Cancer treatment with small molecules - your guide to trends and revenue prospects What does the future hold for small targeted agents to treat cancers? Visiongain's updated report gives you revenue predictions to 2023. There you find sales data, R&D trends, opportunities and commercial prospects. You see the potential of those molecularly-targeted technologies and products. Our new analysis lets ... read more
  • Posted at 5:36 AM announces that a new market research report is available in its catalogue: Global Markets and Technologies for Voice Recognition REASONS FOR THE STUDY AND ITS IMPORTANCE In the coming decade, observers of the evolution in voice recognition technologies will no doubt look back to 2012 as the tipping point year - the time when speech adoption finally broke away from the enterprise niche market of interactive voice response (IVR) solutions into broader uses that include consumer and health care sectors. ... read more
  • Posted at 5:35 AM
    DURECT Corporation (Nasdaq: DRRX) announced that its licensee, Zogenix Inc. (Nasdaq: ZGNX), today reported positive single-dose pharmacokinetic (PK) results from the Phase 1 clinical trial of Relday((TM)), an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia. According to Zogenix, adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products. (Logo: The Phase 1 clinical trial for Relday was conducted ... read more
  • Posted at 5:32 AM
    Interxion Holding N.V. (NYSE: INXN), a leading European provider of carrier-neutral colocation data centre services, announced today that CFO Josh Joshi is scheduled to speak at the Citi 2013 Global Internet, Media & Telecommunications Conference on Monday, January 7, 2013, from 3:00 to 3:40 p.m. PT. ... read more
  • Posted at 5:32 AM announces that a new market research report is available in its catalogue: Orphan Drugs: Market Environment Products and Companies .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication For the pharma and diagnostic industries, rare diseases can provide significant commercial success. Examples of blockbuster orphan drugs include Novartis' leukaemia drug, Glivec/Gleevec (imatinib), with global sales of US$4,695 million in 2011; and Actelion's Tracleer (bosentan), the current gold standard in pulmonary arterial hypertension with sales of CHF1,522 million (US$1,598 million) in 2011. The combination of government incentives to ... read more
  • Posted at 5:30 AM
    Welsh, Carson, Anderson & Stowe (“WCAS”), a private equity firm exclusively focused on information/business services and healthcare, today announced the completion of the acquisition of GetWellNetwork®, Inc., the leading provider of Interactive Patient Care™ solutions. The GetWellNetwork solution is deployed in over 30,000 hospital beds ... read more
  • Posted at 5:30 AM
    Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated the second of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type (Cav2.2) calcium channel blocker for the ... read more
  • Posted at 5:30 AM
    Today Biogen Idec (NASDAQ: BIIB) reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS). The trial did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the ... read more
  • Posted at 5:30 AM
    Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development ... read more
  • Posted at 5:30 AM
    22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction and smoking cessation products, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the N-methylputrescine oxidase (MPO) gene technology. MPO ... read more
  • Posted at 5:30 AM
    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present an update on the company's product portfolio at the J.P. Morgan Healthcare Conference in San Francisco on January 7, 2013 at 1:30pm Pacific time (see webcast details below). In December 2012, Rigel initiated a Phase 1 clinical study of R348, a topical JAK/SYK inhibitor, as a potential therapeutic for chronic dry eye and expects to initiate a Phase 2 ... read more